tiprankstipranks
Trending News
More News >
Immutep (IMMP)
NASDAQ:IMMP

Immutep (IMMP) AI Stock Analysis

Compare
669 Followers

Top Page

IM

Immutep

(NASDAQ:IMMP)

Rating:43Neutral
Price Target:
$1.50
▼(-8.54%Downside)
Immutep's stock is primarily influenced by its challenging financial performance and poor technical indicators. Financials are weak due to negative margins and cash flow issues, mitigated slightly by a solid balance sheet. Technical analysis shows bearish momentum. The valuation is low due to consistent losses, resulting in an overall low stock score.
Positive Factors
Clinical trial results
Immutep reported positive response data from the ongoing P1 INSIGHT-003 study evaluating the triple combination of eftilagimod + chemotherapy + Keytruda in 1L metastatic non-small cell lung cancer, demonstrating a 60.8% overall response rate and 90.2% disease control rate.
Financial stability
The company has a strong cash position, expecting to be funded through the end of 2026.
Regulatory progress
Immutep has requested a meeting with the FDA to discuss the path forward, indicating progress in regulatory engagement.
Negative Factors
Competitive landscape
Survival data from the INSIGHT-003 study showed a median overall survival of 32.9 months and a 24-month overall survival rate of 81.0%, which must compete with existing therapies.
Subgroup performance
In the TPS <50% subgroup, the triple combo demonstrated a 59.6% overall response rate vs. 40.8% for historical control.

Immutep (IMMP) vs. SPDR S&P 500 ETF (SPY)

Immutep Business Overview & Revenue Model

Company DescriptionImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
How the Company Makes MoneyImmutep makes money through the development and commercialization of its proprietary immunotherapy products. The company's primary revenue streams include licensing agreements, milestone payments, and royalties from partnerships with major pharmaceutical companies. Immutep collaborates with industry leaders to advance its products through clinical trials, which can result in upfront payments and subsequent financial compensation upon achieving specific development or sales milestones. Additionally, Immutep may receive funding and grants to support its research and development activities, contributing to its overall earnings.

Immutep Financial Statement Overview

Summary
Immutep's financials reflect typical challenges faced by biotechnology firms in the development phase. The income statement shows ongoing losses and negative margins, but the balance sheet remains stable with strong equity and low leverage. Cash flow is significantly negative due to high R&D expenditures, mitigated by substantial financing efforts.
Income Statement
42
Neutral
Immutep displays a challenging income statement with a negative gross profit margin and consistently negative net income. Revenue growth has been volatile, with recent growth from a low base. The EBIT and EBITDA margins are deeply negative, reflecting ongoing operational and structural challenges. The company’s financial trajectory indicates difficulty in achieving profitability in the near term, common in biotechs during extensive R&D phases.
Balance Sheet
58
Neutral
The balance sheet shows a strong equity position with low debt levels, resulting in a favorable debt-to-equity ratio. The equity ratio is robust, highlighting financial stability and a solid asset base. However, the continuous losses and cash burn could pressure equity if not offset by ongoing financing activities, a typical scenario in the biotechnology sector.
Cash Flow
50
Neutral
Cash flow analysis reveals negative operating and free cash flows as expected in an R&D-intensive biotech firm. Operating cash flow to net income ratio is not favorable, indicating significant cash burn relative to revenue generation. Free cash flow remains negative, but the company has managed significant financing to support operations, a critical factor for sustaining R&D activities.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue4.88M3.84M3.51M170.37K3.97M7.49M
Gross Profit-41.56M-37.70M1.44M-1.89M1.90M-14.99M
EBITDA-48.74M-44.54M-39.57M-31.87M-17.77M-13.46M
Net Income-43.87M-42.72M-39.90M-32.21M-29.90M-13.47M
Balance Sheet
Total Assets182.33M201.58M147.45M102.17M82.03M46.60M
Cash, Cash Equivalents and Short-Term Investments159.26M181.88M123.42M80.00M60.13M26.32M
Total Debt1.68M1.59M1.23M1.73M2.82M9.05M
Total Liabilities9.86M12.06M10.98M8.09M8.76M13.30M
Stockholders Equity172.47M189.52M136.47M94.08M73.27M33.30M
Cash Flow
Free Cash Flow-46.43M-35.75M-35.93M-30.25M-17.66M-10.86M
Operating Cash Flow-45.96M-34.82M-35.88M-30.23M-17.64M-10.84M
Investing Cash Flow-73.32M-21.02M-31.00K-22.91K-15.60K-19.35K
Financing Cash Flow95.24M95.18M76.04M50.33M52.68M20.48M

Immutep Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.64
Price Trends
50DMA
1.80
Negative
100DMA
1.79
Negative
200DMA
1.92
Negative
Market Momentum
MACD
-0.07
Positive
RSI
42.80
Neutral
STOCH
51.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.72, below the 50-day MA of 1.80, and below the 200-day MA of 1.92, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 42.80 is Neutral, neither overbought nor oversold. The STOCH value of 51.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMP.

Immutep Risk Analysis

Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Immutep Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$354.00M-41.31%-7.93%
47
Neutral
$295.25M-30.47%-22.66%
46
Neutral
C$190.36M-4.25-8.56%3.09%13.53%-1.76%
44
Neutral
$314.34M-32.89%27.92%
44
Neutral
$212.89M-29.93%3.38%-36.40%
43
Neutral
$229.01M-31.16%15.14%
41
Neutral
$380.82M-23.68%14.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMMP
Immutep
1.64
-0.24
-12.77%
ATXS
Astria Therapeutics
5.36
-3.61
-40.25%
YMAB
Y-Mabs Therapeutics
4.51
-6.86
-60.33%
ITOS
iTeos Therapeutics
9.97
-4.47
-30.96%
AVIR
Atea Pharmaceuticals
3.60
0.37
11.46%
CMPX
Compass Therapeutics
2.60
1.72
195.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 18, 2025